<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00511212</url>
  </required_header>
  <id_info>
    <org_study_id>MCSGO-0701</org_study_id>
    <nct_id>NCT00511212</nct_id>
  </id_info>
  <brief_title>Intravenous Immunoglobulin in Combination Therapy With Antibacterial Agents for SSI of the Lower Digestive Tract</brief_title>
  <official_title>Clinical Study of Intravenous Immunoglobulin (IVIG) in Combination Therapy With Antibacterial Agents for Surgical Site Infection of the Lower Digestive Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the clinical usefulness of IVIG in combination therapy
      with antibacterial agents for severe peritonitis after lower digestive tract surgery.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    No eligible patient.
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Anticipated">June 2009</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>clinical efficacy</measure>
    <time_frame>at day 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>clinical efficacy, recurrence rate, mortality, time between drug administration and defervescence, defervescence rate,time between drug administration and disappearance of clinical symptoms, improvement rate on clinical symptoms</measure>
    <time_frame>at day 3 and at the end of test drug administration,</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Peritonitis</condition>
  <condition>Postoperative Complications</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous immunoglobulin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients who have obvious symptoms and observation of post-surgical peritonitis, and meet
        the criteria described bellow.

          1. Patients with &gt;=38 degrees C, &gt;=15,000/mm3 or &lt;=3,000/mm3 of WBC and &gt;=10mg/dL of CRP

          2. Patients who have no abscess on the abdominal image

          3. Patients who were administered antibacterial agents for 1 day or more, and show no
             sign of improvement

          4. Patients who are 20 years old or older

          5. Patients who have signed the agreement for participation in this study

        Exclusion Criteria:

          1. Patients who have a history of hypersensitivity to any of the ingredients of
             Immunoglobulin products

          2. Patients who have a history of shock due to any of the ingredients of Immunoglobulin
             products

          3. Patients who were administered immunoglobulin within 1 month before entry

          4. Patients who were administered antibacterial agents for 1 day or more, and show signs
             of improvement

          5. Patients with IgA deficiency

          6. Patients with hereditary fructose intolerance

          7. Patients with history of allergy or adverse effect for antibacterial agents

          8. Patients who have underlying or concomitant disease that may seriously affect the
             assessment of this study

          9. Patients who are or could be pregnant

         10. Patients who have noninfectious fever, fungal infection or viral illness

         11. Other patients who are judged to be inadequate to participate in this study by their
             physician
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Morito Monden, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Multicenter Clinical Study Group of Osaka</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 1, 2007</study_first_submitted>
  <study_first_submitted_qc>August 2, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2007</study_first_posted>
  <last_update_submitted>July 20, 2011</last_update_submitted>
  <last_update_submitted_qc>July 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2011</last_update_posted>
  <keyword>severe peritonitis</keyword>
  <keyword>SSI</keyword>
  <keyword>lower digestive tract surgery</keyword>
  <keyword>Severe peritonitis after lower digestive tract surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Postoperative Complications</mesh_term>
    <mesh_term>Peritonitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins, Intravenous</mesh_term>
    <mesh_term>gamma-Globulins</mesh_term>
    <mesh_term>Rho(D) Immune Globulin</mesh_term>
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

